home All News open_in_new Full Article

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Recommendation based on CABINET Phase III trial results, which demonstrated statistically significant and clinically meaningful reductions in risk of disease progression or death […]


today 6 h. ago attach_file Economics

attach_file Other
attach_file Culture
attach_file Economics
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Events
attach_file Economics
attach_file Sport
attach_file Transport
attach_file Economics
attach_file Politics
attach_file Events
attach_file Economics
attach_file Other
attach_file Transport
attach_file Other
attach_file Other


ID: 1850955267
Add Watch Country

arrow_drop_down